Not on air · 3 of 3 networks checked
Eisai Oncology Medical
- eisai.com
- Healthcare & Life Sciences
- 23 employees
Eisai Oncology Medical’s ads on LinkedIn, Meta and Google, recorded by adsrunning. Browse the latest here for free. Sign up free to see all 41. Watch Eisai Oncology Medical with Starter to get each new one in your feed.
Watchlist with Starter · $49/mo
| Network | Status | Live ads | Nov 2025LinkedIn activity · 52 weeksNov 2026 | Checked | Next step |
|---|---|---|---|---|---|
| None recorded | 0 | Checked 30 Oct 2026 | See all 41 ads → | ||
| Meta | None recorded | 0 | No active ads recorded on the Meta Ad Library | Checked 20 Oct 2026 | Collect them with the API → |
| None recorded | 0 | No ads found on the Google Ads Transparency Center | Checked 28 Oct 2026 | Collect them with the API → |
Eisai Oncology Medical has no live LinkedIn ads. Its Facebook page had no active ads on 20 Oct 2026, and we recorded no Google ads on 28 Oct 2026.
Latest ads
- LINKEDIN · VIDEORecorded 17 Sept 2026
Enrollment is now open for our randomized dose optimization study of E7386 in combination with other anticancer drug(s) in patients with endometrial carcinoma. For more information, email: [email protected] Click to learn more about the study enrollment criteria: https://ow.ly/UKl150X3OVz #endometrialcarcinoma #clinicaltrial #oncology #EC
- LINKEDIN · IMAGERecorded 17 Sept 2026
The 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer are now available. Differentiated thyroid cancer is the most prevalent type of thyroid cancer and among the most frequently diagnosed cancers in the US. https://ow.ly/X5gt50X5a8J #ThyroidCancer #Oncology
- LINKEDIN · VIDEORecorded 17 Sept 2026
What is the mechanism of action (MOA) of an antibody-drug conjugate (ADC)? Learn more about ADCs and how they work from experts in the video below, and visit our website for more information about breast cancer: https://ow.ly/eroW50X30tL
- LINKEDIN · VIDEORecorded 17 Sept 2026
Antibody-drug conjugates (ADCs) are beginning to transform the treatment landscape for metastatic breast cancer (mBC). Experts from the breast cancer field discuss this burgeoning treatment option below. To learn more information about breast cancer, visit our website: https://ow.ly/KXnW50X30aU
- LINKEDIN · VIDEORecorded 17 Sept 2026
Our dose optimization study is still recruiting, with David Scott Miller, M.D., F.A.C.O.G., F.A.C.S., as an investigator. The objective of this study is dose optimization of E7386 in combination with other anticancer drug(s) in patients with endometrial carcinoma. Click to learn more about the study enrollment criteria: https://ow.ly/XBy650X3OBH #endometrialcarcinoma #clinicaltrial #oncology #EC
- LINKEDIN · VIDEORecorded 17 Sept 2026
Experts continue to search for new ways to address unmet needs in metastatic breast cancer (mBC). Watch below to hear some of the leading voices from around the world weigh in on this conversation, and view our website to learn more about breast cancer: https://ow.ly/okoe50X2ZWx
6 of 41 adsSign up to see every Eisai Oncology Medical ad, filter by format and date, and get alerts on new ones.
See all 41 adsWatch the companies you care about.
Filter every ad by industry, country, format and network, and get alerts when a company you watch starts running new ads.